RxDoctor Payments Data

Leah Canjura

Family · New York, NYNPI 1295416782

Payments from drug & device makers

$1,564in general payments, 2019–2025

Across 34 payments — averaging $46.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$883
  • Sumitomo Pharma America, Inc.$434
  • Ferring Pharmaceuticals Inc.$80
  • AbbVie$58
  • Hollister Incorporated$31
  • ABC Home Medical Supply, Inc.$31
  • plus $47 from 2 others

What the payments were for

  • Travel & lodging$54535%
  • Food & beverage$1,02065%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.7$883
Sumitomo Pharma America, Inc.19$434
Ferring Pharmaceuticals Inc.2$80
AbbVie2$58
Hollister Incorporated1$31
ABC Home Medical Supply, Inc.1$31
Immunitybio, Inc.1$27
Tolmar, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,564 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$28,152
Medicare patients
119
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron181$114,345
MyrbetriqMirabegron85$57,485
Estradiol102$5,567
Trospium Chloride43$2,425
Tamsulosin Hcl36$383
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst30$362
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip16$322
Finasteride22$278
Amitriptyline Hcl11$126
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim43$122
Cephalexin15$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$434$114,345181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →